LINTEC Corporation

7966 TSE Consumer Discretionary Other Products
TSE Prime
¥4,320.00
-4.32%
Delayed · cached 15 min

Fair value analysis

7966
LINTEC Corporation
Consumer Discretionary›Other Products
¥5,650.00
Close used for this calculation
¥4,273.39Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
50/100
Profitability11/25
Returns7/25
Balance Sheet21/25
Efficiency11/25
Growth4/25
Good
Quality radar
50Prof.11/25Ret.7/25Eff.11/25B.Sht21/25Growth4/25
⚖️ Consensus Fair Value / Intrinsic Value (10 models)
¥4,273.39
▼ 24.4% vs the close used
Range: ¥285.64 – ¥6,037.35
● OVERVALUED
¥4,273.39 fair value
🎯 Price Target Range & 52W Position
Bear¥285.64Fair Value¥4,273.39Bull¥6,037.35
FairNow
52W Low ¥3,565.0052W High ¥7,310.00

52W range measured from stored price history, not estimated.

📈 Valuation Summary
Trading Significantly Above Fair Value
LINTEC Corporation closed at ¥5,650.00 — 32.2% above the consensus fair value of ¥4,273.39 drawn from 9 valuation models. P/E of 16.3x against the sector multiple the P/E model uses.
All 10 Valuation Models
DCF Valuation
¥3,592.32
-36.4%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=1.1%, r=10%, tg=3%, n=10yr
Graham Number
¥4,832.04
-14.5%
√(22.5 × EPS × BVPS)
EPS=264.48, BVPS=3923.61 · outside Graham range (P/E 21.4, P/B 1.4) — asset-light, treat as a rough floor
P/E Fair Value
¥5,289.60
-6.4%
EPS × 20x (sector P/E)
EPS=264.48, Sector P/E=20x
Peter Lynch (PEG)
¥285.64
-94.9%
EPS × Growth% (PEG = 1 is fair)
EPS=264.48, g=1.1%
EV/EBITDA
¥6,037.35
+6.9%
(EBITDA × 10.5x − Net Debt) ÷ Shares
EBITDA=37.88B
Dividend Discount (DDM)
¥1,404.73
-75.1%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=110.18, r=10%, g=2%
Book Value (P/B)
¥2,186.01
-61.3%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=3923.61, ROE=6.9%, g=3%, r=10%
Reverse DCF
¥5,650.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 8% | Historical: 1.1%
Margin of Safety
¥3,428.49
-39.3%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=4571.32, MoS=25%
📊 Historical P/E Band

10-year P/E range — where does today's valuation sit historically?

Value zoneFair zonePremium zoneCurrent P/E
Sector 20.0xNow 16.3x
0x5x10x15x20x25x30x35x40x45x50x
Value ZoneFair ZonePremium
Fair Zone — around sector rangeCurrent P/E: 16.3xSector P/E: 20.0x-18.4% vs sector avg
Key Metrics
ROE
6.90%
Benchmark: > 15%
✗ Below benchmark
ROCE
9.09%
Benchmark: > 15%
✗ Below benchmark
PAT Margin
5.44%
Benchmark: > 10%
✗ Below benchmark
D/E Ratio
0.33x
Benchmark: < 0.5x
✓ Good
Current Ratio
2.97x
Benchmark: >= 1.2x
✓ Good
EPS (TTM)
¥264.48
Benchmark: Higher is better
P/E Ratio
16.33x
Benchmark: < 25x
✓ Good
ICR
77.40x
Benchmark: > 3x
✓ Good

Computed on September 17, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Formula Guide

🪮 Financial DNA Score — How it's Calculated

Scored 0–100 across four equal pillars (0–25 each). Higher = stronger business quality.

Profitability (0–25)
PAT Margin + EPS Growth
  • PAT >20% → 15pts | >10% → 10pts | >5% → 5pts
  • EPS growth >15% → 10pts | >8% → 7pts | >0% → 4pts
Returns (0–25)
ROE + ROCE + PE Sanity
  • ROE >20% → 10pts | >15% → 7pts | >10% → 4pts
  • ROCE >20% → 8pts | >15% → 5pts
  • PE <25x → 7pts | <35x → 5pts
Balance Sheet (0–25)
D/E + Current Ratio + Cash PAT
  • D/E=0 → 10pts | <0.5x → 7pts | <1x → 4pts
  • CR >1.5x → 8pts | >1.2x → 5pts
  • Cash PAT >1x → 7pts | >0.7x → 4pts
Efficiency (0–25)
Justified P/B + Dividend + Earnings Yield
  • P/B < justified P/B → 10pts
  • Div Yield >2% → 8pts | >1% → 5pts
  • Earnings Yield >5% → 7pts | >3% → 4pts
TCS example: ROE 51.8% (10) + ROCE 63% (8) + PE 15.6x (7) + PAT 18.5% (10) + D/E 0 (10) + CR 1.5x (8) + Div 1.8% (5) = 73/100 Strong
⚖️ Consensus Fair Value — How it's Calculated

Uses a sector-weighted composite — not a simple average — to prevent outlier models from distorting results.

Consensus = Σ(Model Value × Weight) ÷ Σ(Weights)
IT / Pharma / FMCG
  • DCF — 50%
  • P/E Fair Value — 30%
  • Peter Lynch PEG — 20%
Banks / NBFCs
  • Book Value (RIM) — 50%
  • P/E Fair Value — 30%
  • DDM — 20%
Cyclical / Metals / Auto
  • EV/EBITDA — 50%
  • DCF — 30%
  • P/E Fair Value — 20%
Conglomerate / General
  • DCF — 40%
  • P/E Fair Value — 35%
  • EV/EBITDA — 25%
⚠️ The Graham Number is shown for all stocks; for asset-light companies (ROE >40%, or ROE >20% with P/B >6) it reads low and is captioned as a rough floor. The Graham Formula is still excluded for those and for financial companies.
📐 10 Valuation Models — Formulas & Sector Guide
ModelFormulaBest ForAvoid When
1. DCFΣ[FCF×(1+g)ⁿ/(1+r)ⁿ] + TV/(1+r)¹⁰IT, Pharma, FMCGBanks, cyclicals, negative FCF
2. Graham Number√(22.5 × EPS × BVPS)Asset-heavy value stocksIT, FMCG (ROE>40%)
3. Graham FormulaEPS × (8.5 + 2g) × 6.5 ÷ Bond YieldINR stocks, moderate growthAsset-light, US stocks
4. P/E Fair ValueEPS × Sector PE MultipleUniversalLoss-making companies
5. Peter Lynch PEGEPS × Growth% (PEG=1 is fair)Growth companiesLow-growth, cyclicals
6. EV/EBITDA(EBITDA × Multiple − Net Debt) ÷ SharesMetals, cement, autoBanks, FMCG, asset-light
7. DDMD₁ ÷ (r − g), D₁ = D₀×(1+g)Banks, utilities, mature payersNon-dividend, growth stocks
8. Justified P/B (RIM)BVPS × (ROE−g) ÷ (r−g)Banks, NBFCs, insuranceIT, FMCG asset-light
9. Reverse DCFSolve g: Price = Σ[EPS/(1+r)ⁿ] + TVAll stocks (diagnostic)—
10. Margin of SafetyAvg(DCF, Graham, P/E) × 75%Conservative investorsHigh-growth stocks
SectorPrimary (50%)Secondary (30%)Third (20%)Sector PE
IT / SoftwareDCFP/EPeter Lynch25x
PharmaDCFP/EPeter Lynch28x
FMCG / ConsumerDCFP/EGraham Formula30x
BanksBook Value RIMP/EDDM18x
NBFCBook Value RIMP/EEV/EBITDA25x
Insurance / AMCP/EBook ValueDCF40x / 30x
AutoEV/EBITDADCFP/E22x
Metals / SteelEV/EBITDABook ValueDCF8x
Utilities / PowerEV/EBITDADCFP/E18x
Real EstateBook Value (NAV)DCFP/E25x
ConglomerateDCFP/EEV/EBITDA20x
💧 Liquidity Stack — Formulas Explained

Three progressive ratios — each more conservative. Together they reveal the quality of short-term solvency.

Current Ratio
Current Assets ÷ Current Liabilities
  • Includes: Cash + Inventory + Receivables
  • Benchmark: >1.2x ✓ <1.0x ✗
Quick Ratio
(Current Assets − Inventory) ÷ Current Liabilities
  • Excludes inventory (may not liquidate quickly)
  • Benchmark: >1.0x ✓
Cash Ratio (Strictest)
Cash & Equivalents ÷ Current Liabilities
  • Only cash on hand — most conservative
  • Benchmark: >0.2x ✓
Stack Gap Reading
Gap = Current − Quick
  • Gap <0.2 → Low inventory dependency ✓
  • Gap >0.5 → Liquidity depends on selling stock
📏 Key Metrics — Benchmarks Explained
MetricFormulaBenchmarkWhat it Measures
ROENet Profit ÷ Shareholders' Equity>15%Efficiency of equity in generating profit
ROCEEBIT ÷ Capital Employed>15%Returns on all capital (equity + debt)
PAT MarginNet Profit ÷ Revenue>10%Profit per 100 of revenue
D/E RatioTotal Debt ÷ Shareholders' Equity<0.5xFinancial leverage — lower is safer
Current RatioCurrent Assets ÷ Current Liabilities>1.2xShort-term solvency
ICREBIT ÷ Interest Expense>3xCan earnings cover interest?
Cash PATOperating Cash Flow ÷ Net Profit>0.9x<0.9x suggests accounting inflation of profits
DSCR(Net Income + D&A) ÷ Debt Service>1.5xCan the company service its debt?
📊 Live Reference Output — 7966

This stock's full breakdown — DNA score, consensus fair value and every model — is in the Overview & summary and 10 valuation models tabs.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.